Pattarakul Pakchotanon

National Science and Technology Development Agency — Thailand

Medicine · Health Sciences

11h-index312citations27works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(23), COVID-19 Clinical Research Studies(15), Animal Virus Infections Studies(10), Immunotherapy and Immune Responses(4), Mosquito-borne diseases and control(2)

Publications27 total

Distinct systemic immune responses in asymptomatic and symptomatic dengue virus infection
Science Translational Medicine·2025
Age associated SARS-CoV-2 immune responses provide insights into population immunity over four years since the COVID-19 pandemic
Scientific Reports·2025· 4 citedOpen Access
Epitope-dependent complement activation and ADCC by anti-NS1 antibodies in targeting infected cells: Implications for dengue vaccine design
Immunobiology·2025· 2 citedOpen Access
Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections
Scientific Reports·2025· 6 citedOpen Access
Safety and antibody responses of Omicron BA.4/5 bivalent booster vaccine among hybrid immunity with diverse vaccination histories: A cohort study
Vaccine X·2024· 2 citedOpen Access
Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection
Vaccines·2024· 5 citedOpen Access
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
Heliyon·2023· 6 citedOpen Access
Blockade-of-Binding Activities toward Envelope-Associated, Type-Specific Epitopes as a Correlative Marker for Dengue Virus-Neutralizing Antibody
Microbiology Spectrum·2023· 6 citedOpen Access
Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity
International Journal of Infectious Diseases·2023· 8 citedOpen Access
Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years
Journal of Medical Virology·2023· 4 cited
Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3 to 4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
2022· 2 citedOpen Access
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
Frontiers in Immunology·2022· 11 citedOpen Access
Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine
Vaccine·2022· 15 citedOpen Access
Safety and Immunogenicity of Intradermal Administration of Fractional Dose CoronaVac <sup>®</sup> , ChAdOx1 nCoV-19 and BNT162b2 as Primary Series Vaccination
2022· 1 citedOpen Access
Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
Journal of Medical Virology·2022· 26 citedOpen Access
Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
Diagnostics·2022· 20 citedOpen Access
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination
International Journal of Infectious Diseases·2022· 19 citedOpen Access
Strong correlations between the binding antibodies against wild type and neutralizing antibodies against omicron BA.1 and BA.2 variants of SARS-CoV-2 in individuals following booster (third dose) vaccination
2022· 10 citedOpen Access
Persistence of immunity against omicron BA.1 and BA.2 following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-doses AZD1222 vaccination
2022· 2 citedOpen Access
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination
2022· 7 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Thaneeya Duangchinda(26), Warangkana Chantima(23), Sitthichai Kanokudom(21), Nungruthai Suntronwong(21), Yong Poovorawan(21), Suvichada Assawakosri(19), Preeyaporn Vichaiwattana(19), Nasamon Wanlapakorn(19), Natthinee Sudhinaraset(18), Pornjarim Nilyanimit(17), Donchida Srimuan(17), Thanunrat Thongmee(16), Chompoonut Auphimai(15), Thaksaporn Thatsanatorn(14), Sirapa Klinfueng(14), Juthathip Mongkolsapaya(14), Jira Chansaenroj(13), Sittisak Honsawek(10), Ritthideach Yorsaeng(9), Jiratchaya Puenpa(7)